MVC regimen

a chemotherapy protocol consisting of Vinblastine, Carboplatin & Mitomycin; used for the treatment of patients with nonsmall cell lung cancer

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Therapy Context: Research Results

Therapeutics: 1158551
- Drug Therapy: 293145
  - Combination Drug Therapy: 12066
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - MVC regimen: 1
  - Antineoplastic Protocols: 55
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - MVC regimen: 1
- Clinical Protocols
  - Antineoplastic Protocols: 55
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - MVC regimen: 1
Heterocyclic Compounds: 198
Organic Chemicals: 133
- Coordination Complexes: 576
  - Carboplatin: 10368
    - MVC regimen: 1
- Quinones: 434
  - Indolequinones: 12
    - Mitomycins: 11
      - Mitomycin: 7989
        MVC regimen: 1

Experts

1.	Aiestarán, Aintzane: 1 article (01/2014)
2.	Artero, Arturo: 1 article (01/2014)
3.	Bernal, Enrique: 1 article (01/2014)
4.	Blanco, Francisco: 1 article (01/2014)
5.	Crespo, Manel: 1 article (01/2014)
6.	Flores, Juan: 1 article (01/2014)
7.	Garcia, Federico: 1 article (01/2014)
8.	García-Deltoro, Miguel: 1 article (01/2014)
9.	Gutiérrez, Félix: 1 article (01/2014)
10.	Imaz, Arkaitz: 1 article (01/2014)

Related Diseases

1.	Myocardial Infarction 01/01/2014 - "Sixty-two (84%) subjects maintained VL<50 c/mL through week 48, whereas 12 (16%) discontinued treatment: two (3%) withdrew informed consent, one (1%) had a R5→X4 shift in HIV tropism between the screening and baseline visits, one (1%) was lost to follow-up, one (1%) developed an ART-related adverse event (rash), two (3%) died due to non-study-related causes (1 myocardial infarction at week 0 and 1 lung cancer at week 36), and five (7%) developed protocol-defined virological failure, although two of them regained VL<50 c/mL with the same MVC regimen (Table 1). "
2.	Lung Neoplasms (Lung Cancer) 01/01/2014 - "Sixty-two (84%) subjects maintained VL<50 c/mL through week 48, whereas 12 (16%) discontinued treatment: two (3%) withdrew informed consent, one (1%) had a R5→X4 shift in HIV tropism between the screening and baseline visits, one (1%) was lost to follow-up, one (1%) developed an ART-related adverse event (rash), two (3%) died due to non-study-related causes (1 myocardial infarction at week 0 and 1 lung cancer at week 36), and five (7%) developed protocol-defined virological failure, although two of them regained VL<50 c/mL with the same MVC regimen (Table 1). "
3.	Exanthema (Rash) 01/01/2014 - "Sixty-two (84%) subjects maintained VL<50 c/mL through week 48, whereas 12 (16%) discontinued treatment: two (3%) withdrew informed consent, one (1%) had a R5→X4 shift in HIV tropism between the screening and baseline visits, one (1%) was lost to follow-up, one (1%) developed an ART-related adverse event (rash), two (3%) died due to non-study-related causes (1 myocardial infarction at week 0 and 1 lung cancer at week 36), and five (7%) developed protocol-defined virological failure, although two of them regained VL<50 c/mL with the same MVC regimen (Table 1). "